{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-020803","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2023-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.319358+00:00","generated_at":"2026-06-14T03:15:03.525112+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ZyVersa receives Nasdaq delisting notice for $1.00 bid price non-compliance","bullets":["Received Nasdaq notice on June 9, 2023 for failing to maintain $1.00 minimum bid price over 30 consecutive business days.","Has 180 calendar days, until December 6, 2023, to regain compliance by closing at or above $1.00 for 10 consecutive business days.","If not cured, may seek a second 180-day period if it meets other listing standards and notifies intent to cure.","Failure to regain compliance could lead to delisting; company may appeal to Nasdaq hearings panel.","Company states there is no assurance it will regain compliance or secure an extension."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-020803","json":"https://secwatch.observer/filing/0001493152-23-020803.json","markdown":"https://secwatch.observer/filing/0001493152-23-020803.md","text":"https://secwatch.observer/filing/0001493152-23-020803.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223020803/0001493152-23-020803-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223020803/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T03:15:03.525112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7913f7b4b4169a73e5a04f965741dba9bde52a3b","claim":"ZyVersa Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"June 9, 2023, ZyVersa Therapeutics, Inc. (the “ Company ”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “ Notice ”). The Notice has no immediate effect on","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315223020803/0001493152-23-020803-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}